Update shared on01 Aug 2025
Fair value Decreased 7.33%Despite sharply improved consensus revenue growth forecasts, a significant rise in the company's future P/E multiple has driven analysts to lower Ekso Bionics Holdings' fair value estimate from $37.50 to $34.75.
What's in the News
- Launched eksoUniversity, an online continuing education platform for physical therapists, offering courses approved for CEUs in over 30 states.
- Demonstrated initial proof-of-concept for AI-enabled capabilities, including the Ekso Voice Agent for intelligent control of exoskeleton devices, developed with NVIDIA hardware and OpenAI tools.
- Announced a 1-for-14.99999 reverse stock split.
Valuation Changes
Summary of Valuation Changes for Ekso Bionics Holdings
- The Consensus Analyst Price Target has fallen from $37.50 to $34.75.
- The Consensus Revenue Growth forecasts for Ekso Bionics Holdings has significantly risen from 21.2% per annum to 31.3% per annum.
- The Future P/E for Ekso Bionics Holdings has significantly risen from 23.66x to 30.65x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.